Author: Aadarsh Patel | EQMint
What’s the deal? Sudarshan Pharma Industries has approved the acquisition of 24,23,675.64 equity shares, equivalent to a 9.50% stake, in MedTherapy Biotechnology Inc., a Delaware-incorporated company in the US. The acquisition will be made in cash, in US dollars, with the transaction subject to legal and commercial due diligence and applicable FEMA requirements.
Why now? The investment gives Sudarshan Pharma an entry point into the US market and is aimed at providing access to MedTherapy Biotech’s customer base, contracts and distribution network. The company also sees an opportunity to expand into new products and services through the investment.
What it means. MedTherapy Biotechnology is a Boston-based cancer cell and gene therapy company founded in 2018 by experts from Harvard and former Novartis executives. It operates as an end-to-end integrated CAR-T Cell CDMO, with a commercial-scale GMP manufacturing facility in New Delhi and a technology development site in Boston, USA.
By the numbers. Sudarshan Pharma will acquire 9.50% of MedTherapy Biotech through 24,23,675.64 common shares with a face value of US$0.0001 each. Separately, promoters Hemal Mehta and Sachin Mehta will each acquire a 1.50% stake, representing 3,82,685.63 shares each. The proposed transaction is targeted for completion by March 31, 2027, subject to the required processes and approvals.
The bigger picture. MedTherapy Biotech’s stated mission is to make cancer cell and gene therapy more affordable and accessible. For Sudarshan Pharma, the investment creates exposure to a specialised healthcare segment while giving the company a route into the US market.
EQMint Take: Sudarshan Pharma is taking a minority stake in a specialised cancer cell and gene therapy business, with the strategic focus extending beyond a financial investment. The key things to watch now are transaction completion, regulatory processes and how quickly the investment translates into new products, customers and business opportunities.
Disclaimer: This article is not an investment advice and is for educational purpose only.
Source: BSE
For more such information visit EQMint
Join our Whatsapp channel for timely updates: Whatsapp
